TBL1X/TBL1XR1 govern β-cell identity through a PAX6-containing gene regulatory network

A Alina A. Walth-Hummel C Celine Jouffe P Peter Weber (Regeneron Pharmaceuticals, Tarrytown, NY) K Karsten Motzler J Julia Geppert M Michael Sterr W Wei Gan (Shenzhen Key Laboratory of Flexible Printed Electronics Technology, School of Science, Harbin Institute of Technology (Shenzhen), University Town 1 , Shenzhen 518055, Guangdong,) I Iwona Szczerbinska A Ann-Christine König S Stefanie M. Hauck (Metabolomics and Proteomics Core, Helmholtz Centre Munich, German Research Center for Environmental Health, Neuherberg, Germany.) R Raul Terron-Exposito D Daniela Hass C Congcong Wang K Kenneth A. Dyar J James G. Lyon H Heiko Lickert C Carina Ämmälä S Stephan Herzig F Frances M. Ashcroft M Mostafa Bakhti P Patrick E. MacDonald M Maria Rohm

Abstract

Abstract A main mechanism of β-cell dysfunction in diabetes is loss of identity, controlled by transcription factors that induce identity gene expression and disallowed gene repression. How transcription factors facilitate simultaneous expression and repression is not fully understood, representing a knowledge gap in diabetes research. We identify the transcriptional co-factors transducin β-like 1 x-linked (TBL1X) and its homolog TBL1X-related (TBL1XR1, together TBL/R1) as crucial regulators of β-cell identity and determinants of diabetes development and progression. β-cell specific TBL/R1 knockout in mice leads to progressive hypoinsulinemia and hyperglycemia. scRNA-sequencing reveals loss of β-cells, emergence of polyhormonal cells, and reduced β-cell maturity upon TBL/R1 knockout. Interactome screens and chromatin immunoprecipitation show TBL/R1 directly regulate insulin promoter activity through a PAX6-HDAC3 gene regulatory network, evident also in human models. TBL/R1 associates with diabetes in humans, thus our study uncovers an additional regulatory layer maintaining β-cell identity crucial for diabetes development and progression.

Article Details

Volume / Issue Vol. 17, Issue 1
Published April 23, 2026
ISSN 2041-1723
Publisher Nature Portfolio

Journal Info

Nature Communications

Nature Portfolio

ISSN: 2041-1723 Open Access Life Sciences

Authors (22)

A

Alina A. Walth-Hummel

C

Celine Jouffe

P

Peter Weber

Regeneron Pharmaceuticals, Tarrytown, NY

K

Karsten Motzler

J

Julia Geppert

M

Michael Sterr

W

Wei Gan

Shenzhen Key Laboratory of Flexible Printed Electronics Technology, School of Science, Harbin Institute of Technology (Shenzhen), University Town 1 , Shenzhen 518055, Guangdong,

I

Iwona Szczerbinska

A

Ann-Christine König

S

Stefanie M. Hauck

Metabolomics and Proteomics Core, Helmholtz Centre Munich, German Research Center for Environmental Health, Neuherberg, Germany.

R

Raul Terron-Exposito

D

Daniela Hass

C

Congcong Wang

K

Kenneth A. Dyar

J

James G. Lyon

H

Heiko Lickert

C

Carina Ämmälä

S

Stephan Herzig

F

Frances M. Ashcroft

M

Mostafa Bakhti

P

Patrick E. MacDonald

M

Maria Rohm